The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
Open accessAbstract
Cefiderocol (S-649266) is a novel parenteral siderophore cephalosporin conjugated with a catechol moiety at the third-position side chain. The in vitro activity of cefiderocol against Pseudomonas aeruginosa was enhanced under iron-depleted conditions, whereas that of ceftazidime was not affected. The monitoring of [thiazole- 14 C]cefiderocol revealed the increased intracellular accumulation of cefiderocol in P. aeruginosa cells incubated under iron-depleted conditions compared with those incubated under iron-sufficient conditions. Cefiderocol was shown to have potent chelating activity with ferric iron, and extracellular iron was efficiently transported into P. aeruginosa cells in the presence of cefiderocol as well as siderophores, while enhanced transport of extracellular ferric iron was not observed when one of the hydroxyl groups of the catechol moiety of cefiderocol was replaced with a methoxy group. We conclude that cefiderocol forms a chelating complex with iron, which is actively transported into P. aeruginosa cells via iron transporters, resulting in potent antibacterial activity of cefiderocol against P. aeruginosa .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG 2 Uptake of [thiazole-14C]cefiderocol into P. aeruginosa PAO1. The test strain was incubated under iron-depleted (ID-CAMHB) and iron-sufficient [ID-CAMHB supplemented with 100 μM ammonium iron(III) citrate] conditions overnight. After the culture was washed and incubated at 37°C for 10 min, 66 μM ammonium iron(III) citrate and 10 μg/ml [thiazole-14C]cefiderocol were simultaneously added. Samples were taken at 0.5, 1, 3, 5, and 10 min and filtered, and the radioactivity was determined by a liquid scintillation counter. The uptake amounts of [thiazole-14C]cefiderocol were significantly different between the cells grown in ID-CAMHB and those grown in CAMHB at all time points (P value < 0.05, by t test).](/paper-figures/132ab66239684357b4097a2dbfe750cc/siderophore-cephalosporin-cefiderocol-utilizes-ferric-iron-transporter-systems-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from binding their primary ligand, FeEnt, with high affinity, and its aposiderophore Ent with 100-200-fold lower affinity (38), KpnFepA_1658, KpnIroN, and KpnFepA_4984 showed different preferences for ferric catecholate complexes and siderophore antibiotics cefiderocol [FeFDC (40,41)] and FeMB-1 (42,43):”
From Siderophore-mediated iron acquisition by Klebsiella pneumoniae (2024) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
ACETYLORNITHINASE OF ESCHERICHIA COLI: PARTIAL PURIFICATION AND SOME PROPERTIES
Vogel, H. J., & Bonner, D. M. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65874-0 · Cited by 4,001
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,457
Comprehensive transposon mutant library of Pseudomonas aeruginosa
Jacobs, M. A., Alwood, A., Thaipisuttikul, I., Spencer, D. H., Haugen, E., Ernst, S., Will, O., Kaul, R., Raymond, C. K., Levy, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036282100 · Cited by 1,129
Woodford, N., Turton, J. F., & Livermore, D. M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00268.x · Cited by 881
Pseudomonas aeruginosa – a phenomenon of bacterial resistance
Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabó, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 751
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 425
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Of Pseudomonas, porins, pumps and carbapenems
Livermore, D. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.247 · Cited by 393
Research works printed but not linked: 4
- Griffiths E. 1978. Iron in biological systems, p 1–27. In Bullen JJ, Griffiths E (ed), Iron and infection. John Wiley & Sons, New York, NY.
- Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. IV: in vivo efficacy in various murine infection models, abstr F1-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
- Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. V: pharmacodynamic assessment in murine thigh infection models, abstr F1-1559. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
- Müller C, Hofer B, Desarbre E, Page MGP. 2010. Enhanced activity of the siderophore monosulfactam BAL30072 (BAL) against Acinetobacter in iron-limited conditions, abstr F1-2133. Abstr 50th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
Cited by
Sorted by citations
Items 101–200 of 357
Trebosc, V., Schellhorn, B., Schill, J., Lucchini, V., Bühler, J., Bourotte, M., Butcher, J. J., Gitzinger, M., Lociuro, S., Kemmer, C., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa370 · Cited by 42
Cefiderocol “under siege”? Understanding the rise of NDM-mediated resistance to novel agents
Warecki, B. A., Tomatis, P. E., Mojica, M. F., Bethel, C. R., Saravia, M. R., Drusin, S. I., Ono, D., Bahr, G., Papp‐Wallace, K. M., Tamma, P. D., et al. (2025) · Chemical Science · doi:10.1039/d5sc02122g · Cited by 44
Stevens, R. W., & Clancy, M. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2334 · Cited by 42
Prospects of coupled iron-based nanostructures in preclinical antibacterial therapy
Han, J., Zeng, S., Chen, Y., Li, H., & Yoon, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114672 · Cited by 42
Role of new antibiotics for KPC-producingKlebsiella pneumoniae
Theuretzbacher, U., Carrara, E., Conti, M., & Tacconelli, E. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa497 · Cited by 41
Daoud, L., Al-Marzooq, F. I., Moubareck, C. A., Ghazawi, A., & Collyns, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277946 · Cited by 39
Rivera‐Izquierdo, M., Ramos‐Bossini, A. J. L., Rivera-Izquierdo, C., López-Gómez, J., Fernández‐Martínez, N. F., Guerrero, P. R., Martín-delosReyes, L. M., Martínez‐Ruiz, V., Moreno-Roldán, E., & Jiménez-Mejías, E. (2021) · Antibiotics · doi:10.3390/antibiotics10010089 · Cited by 39
Huband, M. D., Ito, A., Tsuji, M., Sader, H. S., Fedler, K. A., & Flamm, R. K. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.03.011 · Cited by 39
Self-citationLüscher, A., Gasser, V., Bumann, D., Mislin, G. L. A., Schalk, I. J., & Köhler, T. (2022) · mBio · doi:10.1128/mbio.01498-22 · Cited by 38
Henriksen, A. S., Jeannot, K., Oliver, A., Perry, J. D., Pletz, M. W., Stefani, S., Morrissey, I., Longshaw, C. M., ARTEMIS Study Investigators, Willinger, B., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03836-23 · Cited by 38
Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
Pybus, C. A., Felder-Scott, C. F., Obuekwe, V. C., & Greenberg, D. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01194-20 · Cited by 38
Taheri, Y., Joković, N. M., Vitorović, J., Grundmann, O., Maroyi, A., & Călina, D. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.578823 · Cited by 38
Oueslati, S., Bogaerts, P., Dortet, L., Bernabeu, S., Lakhal, H. B., Longshaw, C. M., Glupczynski, Y., & Naas, T. (2022) · Antibiotics · doi:10.3390/antibiotics11101352 · Cited by 38
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli
Goldberg, J., Nguyen, H., Kumar, V., Spencer, E. J., Hoyer, D., Marshall, E. K., Cmolik, A., O’Shea, M., Marshall, S. H., Hujer, A. M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00255 · Cited by 37
Miyazaki, S., Katsube, T., Shen, H. L., Tomek, C., & Narukawa, Y. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1386 · Cited by 36
What's new in the treatment of multidrug-resistant gram-negative infections?
Mo, Y., Lorenzo, M. P., Farghaly, S., Kaur, K., & Housman, S. T. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.08.007 · Cited by 34
Antisense antibacterial compounds
Pifer, R., & Greenberg, D. E. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.001 · Cited by 34
Giacobbe, D. R., Ciacco, E., Girmenia, C., Pea, F., Rossolini, G. M., Sotgiu, G., Tascini, C., Tumbarello, M., Viale, P., & Bassetti, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s205309 · Cited by 34
Carosso, S., Liu, R., Miller, P. A., Hecker, S. J., Glinka, T. W., & Miller, M. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01164 · Cited by 34
Experimental Methods for Evaluating the Bacterial Uptake of Trojan Horse Antibacterials
Southwell, J. W., Black, C. M., & Duhme‐Klair, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000806 · Cited by 33
Kidd, J. M., Kuti, J. L., & Nicolau, D. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1438408 · Cited by 31
Preventing sepsis development in complicated urinary tract infections
Petrosillo, N., Granata, G., Boyle, B., Doyle, M., Pinchera, B., & Taglietti, F. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1700794 · Cited by 31
Devoos, L., Biguenet, A., Rousselot, J., Bour, M., Plésiat, P., Fournier, D., & Jeannot, K. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.12.021 · Cited by 31
Bassetti, M., Ariyasu, M., Binkowitz, B. S., Nagata, T. D., ECHOLS, R. M., Matsunaga, Y., Toyoizumi, K., & Doi, Y. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s225553 · Cited by 30
Harnessing microbial iron chelators to develop innovative therapeutic agents
Ribeiro, M., Sousa, C. A., & Simões, M. V. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.10.010 · Cited by 31
Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria
Dortet, L., Niccolai, C., Pfennigwerth, N., Frisch, S., Gonzalez, C., Antonelli, A., Giani, T., Hönings, R., Gatermann, S. G., Rossolini, G. M., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad149 · Cited by 30
Egge, S. L., Rizvi, S. A., Simar, S. R., Alcalde, M., Martínez, J. R. W., Hanson, B., Dinh, A. Q., Baptista, R. P., Tran, T. T., Shelburne, S. A., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00127-24 · Cited by 29
Okanda, T., Haque, A., Koshikawa, T., Islam, A., Huda, Q., Takemura, H., Matsumoto, T., & Nakamura, S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.612020 · Cited by 29
How to kill Pseudomonas —emerging therapies for a challenging pathogen
Yaeger, L. N., Coles, V. E., Chan, D. C. K., & Burrows, L. L. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14596 · Cited by 31
Fluorescent sensors of siderophores produced by bacterial pathogens
Kumar, A., Yang, T., Chakravorty, S., Majumdar, A., Nairn, B. L., Six, D. A., Marcondes dos Santos, N., Price, S. L., Lawrenz, M. B., Actis, L. A., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101651 · Cited by 28
Arcari, G., Cecilia, F., Oliva, A., Polani, R., Raponi, G., Sacco, F., Francesco, A. D., Pugliese, F. R., & Carattoli, A. (2023) · Emerging infectious diseases · doi:10.3201/eid2911.230921 · Cited by 28
The Role of Novel Antibiotics in the Management of Diabetic Foot Infection
Mougakou, E., Mastrogianni, E., Kyziroglou, M., & Τζιόμαλος, Κ. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01357-2 · Cited by 28
Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects
Sanabria, C. R., Migoya, E. M., Mason, J. W., Stanworth, S. H., Katsube, T., Machida, M., Narukawa, Y., & Nagata, T. D. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.07.006 · Cited by 28
Echegorry, M., Marchetti, P., Sanchez, C., Olivieri, L., Faccone, D. F., Martino, F., Badola, T. S., Ceriana, P., Rapoport, M., Lucero, C., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13121139 · Cited by 30
Vidal, P., Fernández, S. C., Fito, E. C., Carbajo, L. D. R., Fernández‐Ugidos, P., López-Ciudad, V. J., Olmo, J. N.-D., Rodríguez-Vázquez, A., & Varela, A. I. T. (2025) · Antibiotics · doi:10.3390/antibiotics14020178 · Cited by 27
Ruggiu, F., Yang, S., Simmons, R. L., Casarez, A. D., Jones, A. K., Li, C., Jansen, J. M., Moser, H. E., Dean, C. R., Reck, F., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00256 · Cited by 27
Potent Antibiotics Active against Multidrug-Resistant Gram-Negative Bacteria
Otsuka, Y. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00842 · Cited by 27
Kufel, W. D., Steele, J. M., Riddell, S. W., Jones, Z., Shakeraneh, P., & Endy, T. P. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00863 · Cited by 27
Rivera, M. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112306 · Cited by 27
Sheldon, J. R., Himmel, L. E., Kunkle, D. E., Monteith, A. J., Maloney, K. N., & Skaar, E. P. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010809 · Cited by 27
In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany
Kresken, M., Korte-Berwanger, M., Gatermann, S. G., Pfeifer, Y., Pfennigwerth, N., Seifert, H., & Werner, G. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106128 · Cited by 25
Forging New Antibiotic Combinations under Iron-Limiting Conditions
Chan, D. C. K., Guo, I., & Burrows, L. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01909-19 · Cited by 25
Metallotherapeutics development in the age of iron-clad bacteria
Centola, G. A., Xue, F., & Wilks, A. (2020) · Metallomics · doi:10.1039/d0mt00206b · Cited by 24
Soriano, C., Montufar, J., & Blandino-Ortiz, A. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/s01.07.2022 · Cited by 24
Scott, Z. W., Choi, S., Britigan, B. E., & Narayanasamy, P. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00050 · Cited by 25
Semisynthesis: An Essential Tool for Antibiotics Drug Discovery
Goel, B., Tripathi, N., Bhardwaj, N., Singh, I. P., & Jain, S. K. (2024) · ChemistrySelect · doi:10.1002/slct.202400554 · Cited by 23
Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and Resistance
Yousefi, B., Kashanipoor, S., Mazaheri, P., Alibabaei, F., Babaeizad, A., Asli, S., Mohammadi, S., Gorgin, A. H., Alipour, T., Oksenych, V., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12112532 · Cited by 23
Burnard, D., Robertson, G. J., Henderson, A., Falconer, C., Bauer, M. J., Cottrell, K., Gassiep, I., Norton, R. E., Paterson, D. L., & Harris, P. N. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00685-20 · Cited by 23
García-Bustos, V., Cabañero-Navalón, M. D., & Salavert, M. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/s02.01.2022 · Cited by 23
Asrat, H., Samaroo-Campbell, J., Ata, S., & Quale, J. M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-23 · Cited by 23
Cercenado, E., Cardeñoso, L., Penin, R., Longshaw, C. M., Henriksen, A. S., & Pascual, Á. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.06.011 · Cited by 23
Valzano, F., Bella, G. L., Lopizzo, T., Curci, A., Lupo, L. I., Morelli, E., Mosca, A., Marangi, M., Melfitano, R., Rollo, T., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04266-23 · Cited by 22
Le, C., Pimentel, C., Pasterán, F. G., Tuttobene, M. R., Subils, T., Escalante, J., Nishimura, B., Arriaga, S., Carranza, A., Mezcord, V., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030600 · Cited by 22
Goldberg, J., Kumar, V., Spencer, E. J., Hoyer, D., Marshall, S. H., Hujer, A. M., Hujer, K. M., Bethel, C. R., Papp‐Wallace, K. M., Pérez, F., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113436 · Cited by 22
Lee, Y. R. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01050-5 · Cited by 22
Gorham, J., Taccone, F. S., & Hites, M. (2022) · Antibiotics · doi:10.3390/antibiotics11050546 · Cited by 21
Li, C., Zhou, P., Liu, Y., & Zhang, L. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s416948 · Cited by 21
Henriksen, A. S., Arena, F., Attwood, M., Cantón, R., Gatermann, S. G., Naas, T., Morrissey, I., Longshaw, C. M., ARTEMIS Study Investigators, Willinger, B., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04181-23 · Cited by 21
He, Y., Wang, Y., Ma, X., Zhao, L., Guan, J., Zhao, J., Yu, W., Li, Y., Ni, W., & Gao, Z. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s392241 · Cited by 20
Emerging Target-Directed Approaches for the Treatment and Diagnosis of Microbial Infections
Almeida, M. C., da Costa, P. M., Sousa, E., & Resende, D. I. S. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01212 · Cited by 20
Natural product inspired antibiotics approved for human use – 1943 to 2025
Butler, M. S., & Capon, R. J. (2025) · Natural Product Reports · doi:10.1039/d5np00067j · Cited by 19
Kim, D. Y., Yeom, S., Park, J., Lee, H., & Kim, H. J. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00556 · Cited by 19
Stracquadanio, S., Nicolosi, A., Privitera, G. F., Massimino, M., Marıno, A., Bongiorno, D., & Stefani, S. (2023) · mSphere · doi:10.1128/msphere.00617-23 · Cited by 19
Jones, B. M., Wagner, J. L., Chastain, D. B., Bookstaver, P. B., Stover, K. R., Lin, J., Matson, H., White, N., Motes, M., & Bland, C. M. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.02.001 · Cited by 19
Shchelik, I. S., & Gademann, K. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00393 · Cited by 19
Über bisherige Denkweisen hinaus – neue Wirkstoffe zur Überwindung der Antibiotika‐Krise
Lakemeyer, M., Zhao, W., Mandl, F. A. M., Hammann, P., & Sieber, S. A. (2018) · Angewandte Chemie · doi:10.1002/ange.201804971 · Cited by 18
Nayak, G., Behera, B., Mohanty, S., Kar, P., & Jena, J. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s378579 · Cited by 18
Llamas, M. A., & Sánchez-Jiménez, A. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-08491-1_2 · Cited by 18
Kanazawa, S., Sato, T., Kohira, N., Ito-Horiyama, T., Tsuji, M., & Yamano, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00576-17 · Cited by 17
Self-citationNaas, T., Lina, G., Henriksen, A. S., Longshaw, C. M., & Jehl, F. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab081 · Cited by 17
Gupta, A., Landman, D., & Quale, J. M. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac022 · Cited by 17
Zhang, Q., Neidig, N., Chu, T., Divoky, C., Carpenter, J., Lee-Hsiao, C., Threatt, H., Sultana, R., & Bush, K. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115651 · Cited by 17
Hogan, A. M., Rahman, A. S. M. Z., Motnenko, A., Natarajan, A., Maydaniuk, D. T., León, B., Batun, Z., Palacios, A., Bosch, A., & Cardona, S. T. (2023) · Nature Communications · doi:10.1038/s41467-023-40494-5 · Cited by 16
DeJonge, B. L. M., Slover, C. M., Nguyen, S., Longshaw, C. M., Takemura, M., Anan, N., Yamashiro, H., & Yamano, Y. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00471-25 · Cited by 16
Self-citationFreiberg, J. A., Tao, L., Manuel, C., Mike, L. A., Nelson, G. E., Harris, B. D., Mathers, A. J., Talbot, T. R., Skaar, E. P., & Humphries, R. M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01507-23 · Cited by 16
Tenero, D. M., Farinola, N., Berkowitz, E. M., Tiffany, C. A., Qian, Y., Xue, Z., Raychaudhuri, A., & Gardiner, D. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.637 · Cited by 16
Kidd, J. M., Abdelraouf, K., & Nicolau, D. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01767-19 · Cited by 16
A Novel Antibiotic Agent, Cefiderocol, for Multidrug-Resistant Gram-Negative Bacteria
Rahman, M. S., & Koh, Y. S. (2020) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2020.50.4.218 · Cited by 16
Iron Uptake Systems: Chemical Tools for Advancing Infectious Disease Treatment and Diagnosis
Ni, D., & Liu, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01023 · Cited by 15
Kimbrough, J. H., Karr, M. H., Nguyen, S., DeJonge, B. L. M., Longshaw, C. M., Takemura, M., Yamano, Y., Castanheira, M., & Mendes, R. E. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02079-25 · Cited by 15
Self-citationGüçlü, A. Ü., Danyildiz, S., Mirza, H. C., Ok, M. A., & BAŞUSTAOĞLU, A. C. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04831-w · Cited by 15
Gant, V. A., Hussain, A., Bain, M., Longshaw, C. M., & Henriksen, A. S. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.07.014 · Cited by 15
Effah, C. Y., Drokow, E. K., Agboyibor, C., Liu, S., Nuamah, E., Sun, T., Miao, L., Wang, J., Xu, Z., Wu, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.597907 · Cited by 15
How to Manage Pseudomonas aeruginosa Infections
Papadimitriou‐Olivgeris, M., Jacot, D., & Guery, B. P. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-08491-1_16 · Cited by 15
Silver, L. L. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_24 · Cited by 15
Bodro, M., Hernández‐Meneses, M., Ambrosioni, J., Linares, L., Moreno, A., Sandoval, E., Olivas, P., Hernández‐Tejero, M., Miró, J. M., Marco, F., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00385-4 · Cited by 15
Kidd, J. M., Abdelraouf, K., & Nicolau, D. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-19 · Cited by 15
Escalante, J., Nishimura, B., Tuttobene, M. R., Subils, T., Mezcord, V., Actis, L. A., Tolmasky, M. E., Bonomo, R. A., & Ramirez, M. S. (2023) · Biomedicines · doi:10.3390/biomedicines11020639 · Cited by 14
Kawai, A., Shropshire, W. C., Suzuki, M., Borjan, J., Aitken, S. L., Bachman, W. C., McElheny, C. L., Bhatti, M. M., Shields, R. K., Shelburne, S. A., et al. (2024) · mBio · doi:10.1128/mbio.02874-23 · Cited by 14
Drugs for Gram-Negative Bugs From 2010–2019: A Decade in Review
Pontefract, B., Ho, H. T., Crain, A., Kharel, M. K., & Nybo, S. E. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa276 · Cited by 14
Azetidines in medicinal chemistry: emerging applications and approved drugs
Cheekatla, S. R. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2610169 · Cited by 13
Metal chelation as an antibacterial strategy for Pseudomonas aeruginosa and Acinetobacter baumannii
Golden, M. M., Heppe, A. C., Zaremba, C. L., & Wuest, W. M. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00175c · Cited by 13
Blank, B. R., Talukder, P., Muir, R. K., Green, E. R., Skaar, E. P., & Renslo, A. R. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00057 · Cited by 14
Daoud, L., Al-Marzooq, F. I., Ghazawi, A., Anes, F., & Collyns, T. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.11.003 · Cited by 13
Novel Antibiotics in the Treatment of Urinary Tract Infections
Naber, K. G., & Wagenlehner, F. R. A. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.11.012 · Cited by 13
Mercadante, S., Tripiciano, C., Romani, L., Nardo, M. D., Bottari, G., Goffredo, B. M., Simeoli, R., Guzzo, I., Lancella, L., Antachopoulos, C., et al. (2023) · Antibiotics · doi:10.3390/antibiotics13010037 · Cited by 12
Jean-Pierre, V., Sorlin, P., Pantel, A., Chiron, R., Lavigne, J., Jeannot, K., Marchandin, H., Collaborative study group on antimicrobial resistance of Achromobacter spp., Amara, M., Cadot, L., et al. (2024) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-024-00709-z · Cited by 12
Marlin, A., Cao, M., Hamouche, J. E., Glaser, O. M., & Boros, E. (2025) · Chemical Science · doi:10.1039/d4sc08509d · Cited by 12
Salleh, M. Z. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102871 · Cited by 12
Robinson, E. A., Wilks, A., & Xue, F. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00895 · Cited by 12
Metadata
- Authors
- Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y.
- Affiliations
- Shionogi (Japan) (JP)
- Corresponding author
- Ito, Akinobu
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7396-7401
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5119021
- OpenAlex
- W2530661320
- Cited by
- 352
- References
- 33
- Citations by year
- 2026: 52 · 2025: 34 · 2024: 35 · 2023: 37 · 2022: 40 · 2021: 37 · 2020: 41 · 2019: 29 · 2018: 30 · 2017: 16 · 2016: 1
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- cefiderocol, siderophore cephalosporin, Pseudomonas aeruginosa, iron chelation, catechol moiety, iron depletion, intracellular accumulation, iron transporters, antibacterial activity, ceftazidime
- MeSH terms
- Cefiderocol, Anti-Bacterial Agents, Biological Transport, Carbon Radioisotopes, Ceftazidime, Cephalosporins, Fluoresceins, Fluorescent Dyes, Iron, Iron Chelating Agents, Microbial Sensitivity Tests, Pseudomonas aeruginosa, Structure-Activity Relationship, Thiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review